LEAD SUBACETATE

US Previously Marketed

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C2H3O2.3Pb.4HO
Molecular Weight	807.7
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[OH-].[OH-].[OH-].[OH-].[PbH2++].[PbH2++].[PbH2++].CC([O-])=O.CC([O-])=O

InChI

InChIKey=ZVYXAPIZECHZKT-UHFFFAOYSA-H

InChI=1S/2C2H4O2.4H2O.3Pb.6H/c2*1-2(3)4;;;;;;;;;;;;;/h2*1H3,(H,3,4);4*1H2;;;;;;;;;/q;;;;;;3*+2;;;;;;/p-6

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21872391https://pubchem.ncbi.nlm.nih.gov/compound/9317 | https://www.fda.gov/Cosmetics/ProductsIngredients/Products/ucm143075.htm

Lead(II) acetate is a white crystalline chemical compound with a sweetish taste. Lead(II) acetate is used as a mordant in textile printing and dyeing, as a drier in paints and varnishes, and in preparing other lead compounds. It was historically used as a sweetener and for cosmetics.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2578
Unknown 2578

PubMed

Title	Date	PubMed
The mechanism of the lead tetraacetate oxidation of a B-norsteroid.	1967 Aug 15	6051709
Chromosomal effects of lead: A critical review.	1980	6779355
Clastogenicity evaluation of seven chemicals commonly found at hazardous industrial waste sites.	1989 Dec	2586542
Hypertrophy and increased glial fibrillary acidic protein are coupled to increased protection against cytotoxicity in glioma cell lines.	1998 Apr	20654395
Scope and mechanism of intramolecular aziridination of cyclopent-3-enyl-methylamines to 1-azatricyclo[2.2.1.0(2,6)]heptanes with lead tetraacetate.	2009 Aug 26	19653649
Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing.	2011 Mar	20865013
The protective effect of flaxseed oil on lead acetate-induced renal toxicity in rats.	2011 Oct 30	21872391
A review of selected chemical additives in cosmetic products.	2014 Nov-Dec	25052592

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

It was examined the associations of increased glial fibrillary acidic protein (GFAP) levels and hypertrophie changes with susceptibility to toxic insult in C6 rat glioma cells. The cells were treated with serial pulses of dibutyryl-cAMP (dBcAMP) (each 48 hr) which increased levels of GFAP approximately twofold and the surface to volume ratio by approximately 1.7 times after the third pulse. This treatment reduced cell number by 22% and increased total protein by 10%. The cells were then exposed to different toxic substances [tin chloride, lead tetraacetate, chloroquine, cadmium chloride, aluminium chloride, mercuric chloride, acrylamide, triethyltin bromide, ethylenediaminetetraacetatic acid (EDTA)] and toxicity to the cells measured by the neutral red (NR) assay. With the exceptions of aluminium chloride and EDTA, 50% effective concentration (EC(50)) values for the toxic substances were increased up to 10,000 times (for cadmium chloride).

Name

Type

Language

LEAD SUBACETATE

Common Name

English

GOULARD'S EXTRACT

Common Name

English

BIS(ACETATE)TETRAHYDROXYTRILEAD

Systematic Name

English

LEAD SUBACETATE [MI]

Common Name

English

LEAD ACETATE BASIC

Common Name

English

Code System Code Type Description

ECHA (EC/EINECS)

215-630-3